Everlywell on Shark Tank: Julia Cheek's $20 Million Ask, Lori Greiner's Credit Line, and a $1.3 Billion Valuation Three Years Later

Yes, Everlywell got a deal on Shark Tank. Julia Cheek pitched her at-home lab-testing company in an episode that aired on November 26, 2017, asked for $1 million for 5%, a $20 million valuation, and made a deal with Lori Greiner. The terms were not a straight equity purchase. Cheek told MedCity News that Greiner offered “a $1 million line of credit for 8 percent interest,” and the company’s own announcement described a $1 million credit line in exchange for 5% equity. Three years later the company was raising money on a different scale: a $175 million Series D in December 2020, which TechCrunch reported valued it at $1.3 billion. Everlywell is still in business in October 2026 under its parent, Everly Health, and Greiner has called it “one of the most successful companies in Shark Tank history.” The numbers behind that line are worth reading carefully, because the one Greiner quotes is not revenue.

The Everlywell Shark Tank deal at a glance

Scroll to see all columns →

Our post-money valuation calculator puts the ask at $20 million. The deal on air was really a loan with equity attached, which is common for Greiner and lets a Shark get paid back before the equity matters.

What Everlywell sells

Everlywell sells lab tests that people order online or in stores, collect at home and mail to a certified lab, with results delivered digitally. Its catalog in October 2026 runs from a $49 cholesterol test to food-sensitivity, hormone, thyroid and STI tests, plus third-party cancer-screening tests. TechCrunch dates the company’s founding in Austin to 2015. Before the show it had already raised $2 million from NextGen Venture Partners, SoGal Ventures, Full Tilt Capital and others, according to MedCity News.

What happened in the Tank

“My ask was $1 million for 5 percent of the company, which was a $20 million valuation,” Cheek told MedCity News after the episode. The company claimed it was the largest valuation deal for a solo female entrepreneur in the show’s history, a claim MedCity reported but did not verify. The deal she made with Greiner is described two ways. MedCity’s own lead says $1 million for a 5% stake; Cheek’s quote in the same article says Greiner offered a $1 million line of credit at 8% interest. The company’s announcement, distributed through a trade group and republished by Food Dive, describes a $1 million line of credit in exchange for 5% equity. The most consistent reading is a credit line plus an equity stake. “It’s important to have a shark on board to sell the brand to the consumer market,” Cheek said.

What happened to Everlywell after Shark Tank

Everlywell became a venture-scale company within three years, and the pandemic was part of why. MedTech Dive reported in December 2020 that it had received an FDA emergency use authorization for an at-home COVID-19 sample collection kit that May, that its tests were in more than 10,000 retail locations including Target, Walgreens, CVS and Kroger, and that sales of most tests were growing “well over 100% year-over-year.” It raised a $175 million Series D, bringing total funding to more than $250 million. TechCrunch reported a $1.3 billion valuation for that round and, in January 2021, a further $75 million from HealthQuest Capital to buy out some existing investors at the same valuation. In March 2021 the company acquired PWNHealth and formed a parent company, Everly Health, led by Cheek, according to TechCrunch.

From $20 million to $1.3 billion: what the stake looks like

The valuation went from the $20 million Cheek asked for in 2017 to $1.3 billion in December 2020, a 65-fold increase in about three years. A 5% stake at $1.3 billion would be worth $65 million before dilution. Everlywell raised more than $250 million after the show, so any 2017 stake would have been diluted along the way; $65 million is an upper bound, not an estimate of what Greiner holds. Our startup dilution calculator shows how each round shrinks an early stake.

The “$1.4 billion in sales” figure

In an update segment that aired in May 2025, Cheek said Everlywell had gone from about $2.5 million in sales the year before the show to “over $1.4 billion in sales,” according to Soap Central’s account. Greiner’s website uses the same figure: “$1.4 Billion in sales since airing 9 years ago.”

That is a cumulative number covering roughly eight years, including the pandemic testing surge. It is not annual revenue, and it is not audited. Everlywell is private and has never published revenue. Spread evenly, $1.4 billion over eight years would be about $175 million a year, but the pandemic years almost certainly carried a larger share, so even that average says little about the business today.

Is Everlywell still in business, and who owns it?

Yes. Everlywell is still selling tests in October 2026; its parent company’s old domain, everlyhealth.com, now redirects to everlywell.com. It is privately held by Cheek, its venture investors and Greiner, whose stake has not been disclosed. “Everlywell and its founder, Julia, are probably one of my proudest outcomes of Shark Tank,” Greiner said, according to Soap Central. We could not verify an official Amazon listing for a specific test, so there is no Amazon link here.

What founders can take from it

First, come to the Tank with a real business behind you. Everlywell had $2.5 million in sales and $2 million in venture money before the episode, so the Shark deal was a marketing partnership rather than survival funding. Second, read the structure, not the headline: a credit line with equity is a very different deal from cash for equity, and the difference was described inconsistently even in the coverage of this one. Third, cumulative sales and valuation are not revenue. Everlywell’s two big numbers, $1.3 billion and $1.4 billion, measure investor pricing and multi-year sales, and neither tells you what the company earns now. For another founder who built a large company after a modest Shark deal, see Bombas.